| 1 |
34954768 | Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy. | 2022 Jun 1 |
2 |
| 2 |
33093222 | F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. | 2021 Jan 5 |
5 |
| 3 |
23041015 | Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. | 2013 Sep 20 |
1 |
| 4 |
23313628 | Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. | 2013 May |
1 |
| 5 |
22459907 | Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. | 2012 Aug |
5 |
| 6 |
21819272 | Vorapaxar: a novel protease-activated receptor-1 inhibitor. | 2011 Oct |
1 |
| 7 |
17303701 | PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. | 2007 May |
1 |
| 8 |
16837456 | PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. | 2006 Sep 8 |
1 |
| 9 |
16194864 | PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. | 2005 Sep |
3 |